Accès gratuit
Numéro
Med Sci (Paris)
Volume 24, Numéro 1, Janvier 2008
Page(s) 56 - 60
Section M/S revues
DOI https://doi.org/10.1051/medsci/200824156
Publié en ligne 15 janvier 2008
  1. Sansonetti P. Plaidoyer pro domo vaccino. Med Sci (Paris) 2007; 23 : 342–4.
  2. Kaufmann SHE, McMichael AJ. Annulling a dangerous liaison : vaccination strategies against AIDS and tuberculosis. Nat Med 2005; 11 : S33–44.
  3. Leclerc C. L’apport des nouvelles technologies en vaccinologie. Med Sci (Paris) 2007; 23 : 386–90.
  4. Guillet JG, Lai MZ, Briner TJ, et al. Interaction of peptide antigens and class II major histocompatibility complex antigen. Nature 1986; 324 : 260–2.
  5. Guillet JG, Lai MZ, Briner TJ, et al. Immunological self, nonself discrimination. Science 1987; 235 : 865–70.
  6. Bouillot M, Choppin J, Cornille F, et al. Physical association between MHC molecules and immunogenic peptides. Nature 1989; 339 : 473–5.
  7. Choppin J, Martinon F, Gomard E, et al. Analysis of physical interactions between peptides and HLA molecules and application to the detection of human immunodeficiency virus 1 antigenic peptides. J Exp Med 1990; 172 : 889–99.
  8. Connan F, Hlavac F, Hoebeke J, et al. A simple assay for detection of peptides promoting the assembly of HLA class I molecules. Eur J Immunol 1994; 24 : 777–80.
  9. Ostankovitch M, Guichard G, Connan F, et al. A partially modified retro-inverso pseudopeptide modulates the cytokine profile of CTL specific for an influenza virus epitope. J Immunol 1998; 161 : 200–8.
  10. Choppin J, Cohen W, Bianco A, et al. Characteristics of HIV-1 Nef regions containing multiple CD8+ T cell epitopes : wealth of HLA-binding motifs and sensitivity to proteasome degradation. J Immunol 2001; 166 : 6164–9.
  11. Culmann-Penciolelli B, Lamhamedi-Cherradi S, Couillin I, et al. Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 nef protein. J Virol 1994; 68 : 7336–43.
  12. Couillin I, Culmann-Penciolelli B, Gomard E, et al. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 Nef protein. J Exp Med 1994; 180 : 1129–34.
  13. Dalod M, Dupuis M, Deschemin JC, et al. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8+ responses in HIV type 1-infected patients : comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol 1999; 73 : 7108–16.
  14. Martinon F, Gras-Masse H, Boutillon C, et al. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J Immunol 1992; 149 : 3416–22.
  15. Deprez B, Sauzet JP, Boutillon C, et al. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 1996; 14 : 375–82.
  16. Bourgault I, Chirat F, Tartar A, et al. Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG- or NEF-specific cytotoxic T lymphocytes by lipopeptides. J Immunol 1994; 152 : 2530–7.
  17. Mortara L, Gras Masse H, Rommens C, et al. Type 1 CD4+ T-cell help is required for induction of anti-peptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J Virol 1999; 73 : 4447–51.
  18. Le Gal FA, Prevost-Blondel A, Lengagne R, et al. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study. Int J Cancer 2002; 98 : 221–7.
  19. Choppin J, Cohen W, Bianco A, et al. Characteristics of HIV-1 Nef regions containing multiple CD8+ T cell epitopes : wealth of HLA-binding motifs and sensitivity to proteasome degradation. J Immunol 2001; 166 : 6164–9.
  20. Cohen W, Bianco A, Connan F, et al. Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1. J Virol 2002; 76 : 10219–25.
  21. Andrieu M, Desoutter JF, Loing E, et al. Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol 2003; 77 : 1564–70.
  22. Molinier-Frenkel V, Lengagne R, Gaden F, et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 2002; 76 : 127–35.
  23. Molinier-Frenkel V, Prevost-Blondel A, Hong SS, et al. The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain. J Biol Chem 2003; 278 : 37175–82.
  24. Gahery-Segard H, Pialoux G, Charmeteau B, et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 2000; 74 : 1694–703.
  25. Gahery-Segard H, Pialoux G, Figueiredo S, et al. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine : characterization of CD8+-T-cell epitopes recognized. J Virol 2003; 77 : 11220–31.
  26. Gahéry H, Choppin J, Bourgault I, et al. HIV preventive vaccine research at the ANRS : the lipopeptide vaccine approach. Thérapie 2005; 60 : 243–8.
  27. Launay O, Durier C, Desaint C, et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers : results of a phase 1 randomized trial. Plos One 2007; 2 : e725 .
  28. Gahéry H, Daniel N, Charmeteau B, et al. New CD4+ and CD8+ T-cell responses induced in chronically HIV-1 infected patients after immunizations with an HIV-1 lipopeptide vaccine. AIDS Res Hum Retr 2006; 22 : 684–94.
  29. Lévy Y, Durier C, Lascaux AS, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20 : 405–13.
  30. Racape J, Connan F, Hoebeke J, et al. Influence of dominant HIV-1 epitopes on HLA-A3/peptide complex formation. Proc Natl Acad Sci USA 2006; 103 : 18208–13.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.